{"name":"Action Pharma A/S","slug":"action-pharma-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOVUE0clcyaGFNSDZrd0ZNWmptWkp6VnZsUGJZbUpJN2VCLWJZaXRuT0pCa2J6Z1JYNFQwZk1EWGVyLWRvYm1nUWtpX2EzWUptQmNfSVpkdnZVYjB4eHJKUXh6Ukg3am8tM05pWVdVVVlDWWJaR0JhZ29Td2p4SHFKUEk3cFFvaGRucy1hQnNVUVB4d3UwN2RNSU1ZdlNvcmoxd3hsUnJnUG1zOTN6WXdZaXJNNDdHZw?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Ascendis Pharma (NASDAQ: ASND) adds shares after warrant exercises - Stock Titan","headline":"Ascendis Pharma (NASDAQ: ASND) adds shares after warrant exercises","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNTm5pZ3owZGx5cW02WUR0LUtNcVNaS2RmOTlvcURTM3FUd19IeGVoQnB3NmdHVXhSbXhLMEhfU05CS3NVaU1TbGF3eHR6YlFtb2hrZkJrSWVBeW5iQ0twNE5zTEswdGV3Z21DOXVWY0szQm01QjJ6U0ZoakZCd1hjLUw4dU9TUkRtN1gtN2dHb09sOHNJS3EyQkR2cnN2MEQxcWNZTl95Z0NGUV94UDhaUFZ3?oc=5","date":"2026-03-12","type":"pipeline","source":"The Boston Globe","summary":"Zealand Pharma CEO says drugmaker will open a Boston research hub - The Boston Globe","headline":"Zealand Pharma CEO says drugmaker will open a Boston research hub","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPRjVqbWc1Y25GM0c3YjY3ZGNxeE5NdkRSVEd4ZG9lT1NTNWctRmR4V3p0M0NfSkVkRnAxVmZMMG85UW9TRzI3a3VzbnNDVU5CYzJ0a0Nua3cyVlVwZkNlaGF4QThVbWttblZIZzRSTDBtbk5NcjREODdwRDcxSGZXMk1mYWZMZnQxQzZ3bEt0RHVGZG9pY25tVlhJbXJQYnExMkRB?oc=5","date":"2026-03-02","type":"pipeline","source":"Meyka","summary":"Outperform Maintained on ASND Ascendis Pharma A/S by Evercore Mar 02, 2026 - Meyka","headline":"Outperform Maintained on ASND Ascendis Pharma A/S by Evercore Mar 02, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOSFV5c0ZjbWtNOHRZRERpbFdsanFyRVFXTnhYN1FMQ2FrZFFId1EtZUxFbTJTTkJZNWZsOHd4U2lFSGZVdjZQR2JXWTBLNWRfaXdtbVBDOWE5X04zaXFYM0dKSG9LU0FXWHoxekhhUWVRR25IMnhQYThrYjQxSXctNUd2VDkzZzh4VDk0cDJEYl9BaHNFWFQ0LUhyemNFRkJJeVlfTGtJaDVfMHNEV1RuVVRhQy1MUllYN0JWVDNfOTY4SlZtZUx0STZZSS1GNWlNSXU1NkROZFRJbldfVmNnUA?oc=5","date":"2026-02-11","type":"earnings","source":"globenewswire.com","summary":"Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results - globenewswire.com","headline":"Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNRG1Mb3kyTDc4V2VPOEw2UHVJaDdQUXNEbjRWaFVqUlVRQ2IyZjhkVjJUNDVrd1lkZ2VaUzJwN293UklkM2NoMDhCV2xMXzJKX3ByaXBlc3FjN3lwSnVyamxxWVIzWWNxcFVER0FtRFZCR3BqMmxkclBXTlMxWmZTTFhhTjJJVURJdnRlVWtkM3ZFYmdmRjNIWl9PZTFvLXpGUGhNbDJ4b0R0MFdsZnVERjRYXzNxdUx1TTJydEpJSERXbk5meVNPTm52dndTbGkzMkZmamNicHM2a0VKTmpQN1p3RUNHNWs?oc=5","date":"2026-01-05","type":"pipeline","source":"Quiver Quantitative","summary":"Ascendis Pharma A/S to Present Business Update at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - Quiver Quantitative","headline":"Ascendis Pharma A/S to Present Business Update at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVXpYY0V2ejdCQ29wZjZUX3dEU2VTUDhlVDlIbzYzNzVQd0ZzVlgyQ3h1cm9fWGhjb1V0NVVmdjJ4ZUtVQmdFNEZ0OC1Za3dpalhBMkhKTTRrTlVCb2NxWk1FQWVyVnJvTFVVU2NrcUZsbFEwRklYTlRCQVJrOWtKNGRYQ0o1eTN1c1BlZ09TdExiMkpNTVVlRFBYMWNEUUpZMnMwUE5ITngxOWItaU1BWFFJM0tWN1Q2QUt2cGpleGZxNFk?oc=5","date":"2025-12-09","type":"pipeline","source":"Benzinga","summary":"Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Benzinga","headline":"Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPZEhfdXFmZllDbzFlTlBaaTZTNFdHeXR3b2tGUEZHeG9RV05fNUNwMXVGNzUtWF9wVGJzZGtSYzV0QWhUdE5fdFl2X2FLa2IyeUZrRmVueWI5SEdpR3lERHhPQlhMYm1JYU1SX3RUWVRmeVVQdnRZWk1ZZWxHUURWSnZqUDc5TkR5d01TaFltQjloUl8wZ0V4WThBMmt4aVd5SFVwbk9DU3JEcjdhN2FRa2tGbTR6dGE1ZXRYQnBmT2ViM2twZ0NJ?oc=5","date":"2025-11-25","type":"pipeline","source":"Quiver Quantitative","summary":"Ascendis Pharma Announces PDUFA Goal Date Extension to February 28, 2026 for TransCon CNP NDA - Quiver Quantitative","headline":"Ascendis Pharma Announces PDUFA Goal Date Extension to February 28, 2026 for TransCon CNP NDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQaWtuRVZsU1pFc0I2ck5JU3BXenlpamM0ZHJEMWJIUXhqdXBHZ21PTjRRcmxySWlJRDF0VzRTY09GME5LUjVoWkwyVzV2Mm9yRXZoTGYxeXNhM0xYWWxLdzhBRV9EUWpWNmgycjlNaldhZF9ib3R1Zzh4cG8xbV83MjV5emNEWUhtZ3JvV3ZVUUxtMVdYVlVVUmdFazNWOXo2Nmk3U1JfTTlzbXR1?oc=5","date":"2025-08-26","type":"pipeline","source":"European Biotechnology Magazine","summary":"Calluna Pharma starts efficacy test with unique IPF antibody - European Biotechnology Magazine","headline":"Calluna Pharma starts efficacy test with unique IPF antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE02VmhrZC00ZG04M19lanpyaXdpc1pWdDY4cnotY2RiaU1uR2dPdlBIdTZKVml5aFdVNlVNQWFkRVZCZXVLRjVBMGhiQ3Y5MzdCZTd3b3g5ZHRUUTJBaHBxMkZkY01aTHBw?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Ascendis Pharma A/S (ASND) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Ascendis Pharma A/S (ASND) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxONTJyd2VyQU9FTzBUTEdsd0F6akNJV0RPVHg2eWtoSktGcVh0STFHQnI4dFV3UUlYdDhrYnQ2eXN3b1Q1RG9OX3VrRFE3V25KaGlGS2RyTUljdTRSMG5id20yN0ZGUzczRkxudTVDdmU0cU1SR2NTZHhXRE9zUWJ0X2thcE51VnliR0FBRkk4WWxydjNkQTRqYlFMVDVlSDNVVF8xRk4tRkxOZHdMNUx5aXdkOXVEeDFfZzBDMldNckQ5Nk1DMkNiNl82eWxtZnYzSFZPc1RvdjdUWWJNS1E5MlhvbU8?oc=5","date":"2025-05-09","type":"trial","source":"BioSpace","summary":"LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis - BioSpace","headline":"LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNYTdabmFuT3o5TTZ6NWxZS2NEWFM2MWVTS1hhRF9JSTB3b0Y1QklHbF9DYmVLRE16a0FibEhiUXJvWUd5RklxMm01OVlibFNvQThtb1o3SjR6REI4VFBvUlk2SUlxN0xaZWExN2NjTDdDb09QZVV6a0o4U09DTF9uWk9MbkU1QjNicVNYRDRDWFp5dThYT2dpWVhLSGt3bWVlbHZzc0VGWkJlZW5JTWhVZVZmSmNZZzRWTkNUNHh1bndiRzdrZFV4WUJVN2t2b29WQWhuTXlCR1AyUERWeG5nTw?oc=5","date":"2025-01-13","type":"patent","source":"PR Newswire","summary":"BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court - PR Newswire","headline":"BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQbjdtRkl4M0Zobk5uYktGTmZpWmhsb09Ddm1sR2dVcXhMcWFKeTdxMGs2OWhHandXdEQ2a2JsVHZwMGw4NjduWnpKTG1Ddkg5QjFfTFlQWUJ6VVB0b2E1aERlOVJjMlJKMkNBN2dvaENfNlNybUtNY0JZRFgtcXE4cmYyenJuOGpKUHJOV3djZUM2NnJIRFNOclRaYWJobVhXcjB4a25aSjRRczNuM2hRcTZQTHZCVS00VnlKX2JGUEprbFdwQ2FxMWpPNUVkcjJ6d0NjRjBZblJWVGxCSkIyWlNtOTJucFRtWHE3Q3dnSndMUXAtY2Jfc2lmOVRwcGM?oc=5","date":"2024-01-22","type":"pipeline","source":"Lowenstein Sandler LLP","summary":"Lowenstein Represents Timber Pharmaceuticals as Special Corporate Counsel in Chapter 11 and Asset Sale to Leo Pharma A/S - Lowenstein Sandler LLP","headline":"Lowenstein Represents Timber Pharmaceuticals as Special Corporate Counsel in Chapter 11 and Asset Sale to Leo Pharma A/S","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}